Cargando…
Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma
BACKGROUND: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antig...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Shiraz University of Medical Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349153/ https://www.ncbi.nlm.nih.gov/pubmed/37456201 http://dx.doi.org/10.30476/ijms.2022.95583.2705 |
_version_ | 1785073839166717952 |
---|---|
author | Gong, Yan Song, Lele Ou, Lei Lu, You-Yong Huang, Xianyong Zeng, Qiang |
author_facet | Gong, Yan Song, Lele Ou, Lei Lu, You-Yong Huang, Xianyong Zeng, Qiang |
author_sort | Gong, Yan |
collection | PubMed |
description | BACKGROUND: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125). METHODS: A retrospective study was conducted at the Chinese People’s Liberation Army General Hospital from May 2014 to September 2018. Serum specimens were collected, and miR-25 expression levels were measured using real-time quantitative polymerase chain reaction. Serum CA19-9, CEA, and CA125 levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses including nonparametric test, receiver operator characteristic (ROC) curves, Kaplan-Meier analysis, and subsequent log-rank test were performed with PRISM 5.0 software. Univariate and multivariate analyses were performed with the R software. P<0.05 was considered statistically significant. RESULTS: A total of 250 individuals were recruited, including 75 with pancreatic ductal adenocarcinoma (PDAC), 75 with benign lesions, and 100 healthy controls. miR-25, CA19-9, CEA, and CA125 exhibited an area under the curve (AUC) of 0.88, 0.91, 0.81, and 0.76 with a sensitivity of 78.7%, 74.7%, 37.3%, and 35.7% and specificity of 91.5%, 97.0%, 98.2%, and 98.3%, respectively. The combination of miR-25 and CA19-9 further increased the sensitivity to 93.3% with a specificity of 88.5%. Stage-dependent sensitivity was observed with CA19-9, CEA, and CA125. miR-25 levels significantly stratified the prognosis by median level (4,989.97 copies/mL). CA19-9, CEA, and CA125 levels significantly stratified the prognosis by median levels. Univariate and subsequent multivariate analyses identified tumor (T) stage, CA19-9, and CA125 as independent risk factors for PDAC prognosis. CONCLUSION: The combination of miR-25 and CA19-9 significantly enhanced the detection sensitivity of PDAC. T stage, CA19-9, and CA125 levels were independent risk factors for PDAC prognosis. |
format | Online Article Text |
id | pubmed-10349153 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Shiraz University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-103491532023-07-16 Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma Gong, Yan Song, Lele Ou, Lei Lu, You-Yong Huang, Xianyong Zeng, Qiang Iran J Med Sci Original Article BACKGROUND: Pancreatic cancer is a malignancy with high mortality due to the difficulties in early detection. We investigated and compared the diagnostic and prognostic performance of several blood biomarkers, including microRNA-25 (miR-25), carbohydrate antigen 19-9 (CA19-9), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125). METHODS: A retrospective study was conducted at the Chinese People’s Liberation Army General Hospital from May 2014 to September 2018. Serum specimens were collected, and miR-25 expression levels were measured using real-time quantitative polymerase chain reaction. Serum CA19-9, CEA, and CA125 levels were measured using enzyme-linked immunosorbent assay (ELISA). Statistical analyses including nonparametric test, receiver operator characteristic (ROC) curves, Kaplan-Meier analysis, and subsequent log-rank test were performed with PRISM 5.0 software. Univariate and multivariate analyses were performed with the R software. P<0.05 was considered statistically significant. RESULTS: A total of 250 individuals were recruited, including 75 with pancreatic ductal adenocarcinoma (PDAC), 75 with benign lesions, and 100 healthy controls. miR-25, CA19-9, CEA, and CA125 exhibited an area under the curve (AUC) of 0.88, 0.91, 0.81, and 0.76 with a sensitivity of 78.7%, 74.7%, 37.3%, and 35.7% and specificity of 91.5%, 97.0%, 98.2%, and 98.3%, respectively. The combination of miR-25 and CA19-9 further increased the sensitivity to 93.3% with a specificity of 88.5%. Stage-dependent sensitivity was observed with CA19-9, CEA, and CA125. miR-25 levels significantly stratified the prognosis by median level (4,989.97 copies/mL). CA19-9, CEA, and CA125 levels significantly stratified the prognosis by median levels. Univariate and subsequent multivariate analyses identified tumor (T) stage, CA19-9, and CA125 as independent risk factors for PDAC prognosis. CONCLUSION: The combination of miR-25 and CA19-9 significantly enhanced the detection sensitivity of PDAC. T stage, CA19-9, and CA125 levels were independent risk factors for PDAC prognosis. Shiraz University of Medical Sciences 2023-07 /pmc/articles/PMC10349153/ /pubmed/37456201 http://dx.doi.org/10.30476/ijms.2022.95583.2705 Text en Copyright: © Iranian Journal of Medical Sciences https://creativecommons.org/licenses/by-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NoDerivatives 4.0 International License. This license allows reusers to copy and distribute the material in any medium or format in unadapted form only, and only so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Original Article Gong, Yan Song, Lele Ou, Lei Lu, You-Yong Huang, Xianyong Zeng, Qiang Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma |
title | Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma |
title_full | Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma |
title_fullStr | Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma |
title_full_unstemmed | Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma |
title_short | Diagnostic and Prognostic Performance of MicroRNA-25, Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 125 in Pancreatic Ductal Adenocarcinoma |
title_sort | diagnostic and prognostic performance of microrna-25, carbohydrate antigen 19-9, carcinoembryonic antigen, and carbohydrate antigen 125 in pancreatic ductal adenocarcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10349153/ https://www.ncbi.nlm.nih.gov/pubmed/37456201 http://dx.doi.org/10.30476/ijms.2022.95583.2705 |
work_keys_str_mv | AT gongyan diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma AT songlele diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma AT oulei diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma AT luyouyong diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma AT huangxianyong diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma AT zengqiang diagnosticandprognosticperformanceofmicrorna25carbohydrateantigen199carcinoembryonicantigenandcarbohydrateantigen125inpancreaticductaladenocarcinoma |